Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Immunology and Inflammation (I&I)pharmaceutical analysis
team
- CHAPTER 1 EXECUTIVE SUMMARY
- Datamonitor insight into the osteoarthritis market
- Related reports
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current seven major market assessment
- The osteoarthritis market totaled nearly $4 billion in 2007
- After three years of decline, osteoarthritis sales increased 0.8% from
2006 to 2007
- US remained the largest osteoarthritis market in 2007,despite the
sharpest decline in sales compared to other major markets
- Rest of world snapshot
- Key brand comparison between the 7MM and rest of the world
- Expensive brands show strong sales in Canada, Australia and the EU,
but Brazil and Mexico offer growth opportunity
- Future seven major market assessment
- Comparison with previous forecast
- The major change occurs in the COX-2 class
- Osteoarthritis market will grow to reach sales of $5.5 billion in 2017
- Osteoarthritis accounts for 15% on average of total branded values
- Forecast data tables
- CHAPTER 3 BRAND DYNAMICS
- Overview of competitive landscape
- Pfizer' s Celebrex was the leading drug for osteoarthritis in 2007
- COX-2
- Celebrex (celecoxib)
- Celebrex' s 7MM sales rise in the near-term but decline beginning in
2011 as pipeline agents followed by generic celecoxib enter the market
- Patent covering Celebrex in the US enforceable until 2014
- Generic versions of Celebrex will not be available until 2019 in Japan
- Arcoxia (etoricoxib)
- Arcoxia performed well in the EU markets from 2004 to 2007
- Non-approvable in the US
- EU patent covering Arcoxia expires in 2017
- Prexige (lumiracoxib)
- Prexige' s marketing authorization withdrawn in multiple regions
- Non-approvable in the US
- Prexige will not be launched in Japan
- GW-406381
- GlaxoSmithKline' s GW-406381 removed from Datamonitor' s forecast
- LAS-34475
- Almirall' s LAS-34475 removed from Datamonitor' s forecast
- Traditional NSAIDs
- Mobic (meloxicam)
- Impact of Mobic patent expiry in the US and five major EU markets
- Generic meloxicam yet to enter Japan
- Naproxcinod
- Phase III program will conclude by the end of 2008
- Datamonitor has pushed back Naproxcinod' s launch date in the US and
EU to Q3 2010
- Datamonitor has upgraded its forecast for naproxcinod
- Diractin (IDEA-033)
- Updated launch date in the EU for 2008
- Diractin outlicensed to Alpharma and US launch updated for 2011
- Potential for Diractin in Japan
- Licofelone
- Licofelone pulled from Datamonitor' s forecast
- PN-400 (naproxen + esomeprazole)
- PN-400 added to forecast update
- Non-narcotic analgesics
- Zucapsaicin
- Zucapsaicin was removed from the forecast update
- Narcotic analgesics
- Fentora (fentanyl)
- FDA advisory panel votes against use of Fentora in non-cancer
breakthrough pain
- Corticosteroids
- CRx-102 (prednisolone + dipyridamole)
- Long-term safety concerns an issue with CRx-102
- Hyaluronic acids
- Synvisc (Hylan GF-20)
- Filed in Japan and launch expected in 2009
- Synvisc-One (Hylan GF-20)
- Single injection Synvisc-One granted EU approval
- US approval of Synvisc-One expected late in 2008
- BIBLIOGRAPHY
- References
- Websites
- Datamonitor reports
- APPENDIX
- Contributing experts
- Methodology
- Indication split calculations
- Assumptions and caveats for diagnosis value estimates
- Generic erosion and pricing assumptions
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor Healthcare' s research and analysis methodlogies
- Datamonitor Healthcare' s therapy area capabilities
- Disclaimer
- List of Tables
- Table 1: Datamonitor' s definition of osteoarthritis by ICD-10 code
- Table 2: Leading branded drug sales ($m) for osteoarthritis in the 7MM,
and the Rest of World (ROW), 2007
- Table 3: Osteoarthritis-specific sales forecasts for the 7MM ($m),
2007-2017
- Table 4: Leading branded drug sales ($m) for osteoarthritis in the 7MM,
2007-2017
- Table 5: Key products in the late-stage R&D pipeline for
osteoarthritis, 2007
- Table 6: Osteoarthritis-specific sales ($m) of Celebrex(celecoxib) in
each of the 7MM, 2004-07
- Table 7: Osteoarthritis-specific sales ($m) of Arcoxia (etoricoxib)in
Germany, Italy, Spain and the UK, 2004-07
- Table 8: Brand erosion of Mobic (meloxicam) following first generic
entrant, by quarter, in US, France, Germany, Italy, Spainand the UK
- Table 9: Naproxcinod: Phase III program for osteoarthritis
- Table 10: Datamonitor' s definition of osteoarthritis by ICD-10 code
- List of Figures
- Figure 1: Osteoarthritis sales in the US, 5EU and Japan,2004-07
- Figure 2: Key events impacting the osteoarthritis market, 2004-08
- Figure 3: Osteoarthritis market sales by class in the 7MM, 2004-07
- Figure 4: Sales performance of the US, 5EU and Japan osteoarthritis
markets, 2006-07
- Figure 5: Comparison of COX-2 class forecasts in the 7MM, 2005-2017
- Figure 6: Osteoarthritis sales by class in the 7MM,2007-2017
- Figure 7: Impact of key events on the osteoarthritis market, 2007-2017
- Figure 8: Market share of drug classes for osteoarthritis, 2007 vs. 2017
- Figure 9: Total market forecast for osteoarthritis and all other
indication sales, split by indication in the 7MM, 2007-2017
- Figure 10: Osteoarthritis-specific sales ($m) forecast for Celebrex in
the seven major markets, 2007-2017
- Figure 11: Osteoarthritis-specific sales ($m) forecastfor Arcoxia in the
EU markets, 2007-2017
- Figure 12: Brand erosion of Mobic (meloxicam) in US,France, Germany,
Italy, Spain and the UK
- Figure 13: Datamonitor' s 2006 and updated sales ($m)forecast for NicOx' s
naproxcinod in the 7MM, 2007-2017
- Figure 14: Datamonitor' s 2006 and updated sales ($m)forecast for Idea' s
Diractin (IDEA-033) in the 7MM, 2007-2017
- Figure 15: Datamonitor' s sales ($m) forecast for Pozen' s PN-400 in the
7MM, 2007-2017
- Figure 16: Datamonitor' s osteoarthritis-specific sales($m) forecast for
Genzyme' s Synvisc in the 7MM, 2007-17
|
Related Report
|
View Cart
